- Home
- BLRX vs CING Comparison
BLRX vs CING Comparison
Compare BLRX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CING
- Stock Information
- Founded
- BLRX 2003
- CING 2012
- Country
- BLRX Israel
- CING United States
- Employees
- BLRX N/A
- CING N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- CING Health Care
- Exchange
- BLRX Nasdaq
- CING Nasdaq
- Market Cap
- BLRX 17.0M
- CING 17.3M
- IPO Year
- BLRX 2011
- CING 2021
- Fundamental
- Price
- BLRX $4.25
- CING $5.50
- Analyst Decision
- BLRX Strong Buy
- CING Strong Buy
- Analyst Count
- BLRX 2
- CING 4
- Target Price
- BLRX $19.00
- CING $30.67
- AVG Volume (30 Days)
- BLRX 36.3K
- CING 104.9K
- Earning Date
- BLRX 08-14-2025
- CING 08-12-2025
- Dividend Yield
- BLRX N/A
- CING N/A
- EPS Growth
- BLRX N/A
- CING N/A
- EPS
- BLRX N/A
- CING N/A
- Revenue
- BLRX $22,340,000.00
- CING N/A
- Revenue This Year
- BLRX N/A
- CING N/A
- Revenue Next Year
- BLRX N/A
- CING N/A
- P/E Ratio
- BLRX N/A
- CING N/A
- Revenue Growth
- BLRX 91.68
- CING N/A
- 52 Week Low
- BLRX $2.30
- CING $1.80
- 52 Week High
- BLRX $35.60
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- BLRX 43.97
- CING 66.64
- Support Level
- BLRX $4.47
- CING $4.25
- Resistance Level
- BLRX $4.75
- CING $6.01
- Average True Range (ATR)
- BLRX 0.30
- CING 0.34
- MACD
- BLRX -0.04
- CING 0.09
- Stochastic Oscillator
- BLRX 11.96
- CING 71.02
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.